Why the Market Dipped But Astrazeneca (AZN) Gained Today

Astrazeneca (AZN) rose 2.25% to $163.78 in the latest session, outperforming the broader market decline. However, the company faces headwinds with consensus EPS estimates down 8.49% over the last 30 days and a Zacks Rank of #4 (Sell). While revenue is expected to grow 5.82% year-over-year, the stock trades at a forward P/E of 17.14, below its industry average, and the Medical-Biomedical and Genetics industry ranks in the bottom 34% of all sectors.